Van Hulzen Asset Management, LLC Crispr Therapeutics Ag Transaction History
Van Hulzen Asset Management, LLC
- $1.32 Billion
- Q4 2024
A detailed history of Van Hulzen Asset Management, LLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Van Hulzen Asset Management, LLC holds 120 shares of CRSP stock, worth $5,749. This represents 0.0% of its overall portfolio holdings.
Number of Shares
120Holding current value
$5,749% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CRSP
# of Institutions
484Shares Held
64.1MCall Options Held
1.64MPut Options Held
1.93M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl8.97MShares$430 Million3.09% of portfolio
-
Capital International Investors Los Angeles, CA8.74MShares$419 Million0.07% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.81MShares$183 Million0.09% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$133 Million0.0% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.2.75MShares$132 Million0.07% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $3.74B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....